**Core tip:** A high prevalence of hepatitis C virus (HCV) infection has been reported in Ukraine and most of the Commonwealth of Independent States regions. The scarcity of adequate epidemiological data, the lack of national guidelines, and multiple socio-economic barriers hinder the effective management of HCV infection in these regions. The current consensus document intends to guide clinicians and healthcare providers on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of HCV infection and to help optimize the treatment outcomes in the region.

INTRODUCTION
============

Epidemiology of hepatitis C virus infection in Ukraine and Commonwealth of Independent States countries
-------------------------------------------------------------------------------------------------------

Hepatitis C is a liver disease caused by hepatitis C virus (HCV), which manifests clinically as acute and chronic hepatitis\[[@B1],[@B2]\]. There are six different genotypes of HCV (GT1-GT6)\[[@B1]\].

In the latest nationwide HCV disease burden estimation by the Polaris Observatory HCV collaborators in about 113 countries, the global prevalence of HCV infection was estimated to be about 1.0% in 2015 (71.1 million viremic HCV-infected individuals)\[[@B3]\]. In a separate analysis of the prevalence data from 109 countries estimated by the World Health Organization, the global epidemic size of HCV infection was found to be 69.6 million HCV-infected individuals in 2016\[[@B4]\]. In another recent, systematic review, the global genotype distribution pattern revealed the predominance of GT1 (49.1%), followed by GT3 (17.9%), GT4 (16.8%), GT2 (11.0%), GT5 (2%), mixed (1.8%), and GT6 (1.4%)\[[@B5]\]. In the same review, the prevalence of HCV infection in Central Asia, which included the Commonwealth of Independent States (CIS) regions of Armenia, Azerbaijan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan, besides Mongolia and Georgia, was found to be 5.8%\[[@B5]\]. The predominant genotype in this region was reported to be GT1 (70.4%), followed by GT3 (19.6%) and GT2 (8.6%). The prevalence of mixed GTs was noted to be rare in this region, with a complete absence of cases of GT4, GT5, and GT6. In the Eastern European zone, which includes, among other countries, Ukraine and the three CIS regions of Belarus, Moldova, and Russia, the prevalence of HCV infection was found to be 3.1%. GT1 was the most predominant genotype (68.1%), followed by GT3 (26.6%), GT2 (4.3%), mixed GTs (0.5%), and GT4 (0.5%). No GT5 and GT6 cases were reported in this region\[[@B5]\]. The lack of robust epidemiological data at a national level and in some extended regions of Central Asia was cited as one of the major setbacks in this review\[[@B5]\].

Another survey was conducted by the Alliance for Public Health (Alliance, Ukraine) in collaboration with the Saint Petersburg-based International Treatment Preparedness Coalition in 11 Eastern Europe and Central Asian countries (including Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Ukraine, and Uzbekistan)\[[@B6]\]. Among the CIS regions and Ukraine, the highest prevalence of HCV infection was reported in Uzbekistan (6.5%), followed by Ukraine (5%); Russia, Armenia, and Kyrgyzstan (4% each); Azerbaijan (3.2%), Tajikistan (2.3%), Belarus (2%-3%), Moldova (1.7%-4.0%), and Kazakhstan (1.5%-3.0%)\[[@B6]\]. Furthermore, the survey reported the lack of adequate HCV epidemiological data required to plan services and resources in the CIS region\[[@B6]\].

Regional unmet needs in the management of HCV infection
-------------------------------------------------------

The dearth of data pertaining to HCV epidemiology, coupled with the disparity in the genotype distribution across Ukraine and the various CIS regions, highlights a clear unmet need in the optimal management of HCV infection in this region\[[@B5],[@B6]\]. Several other unmet needs in the management of HCV infection in the CIS region have also been described in the literature. These include: (1) Lack of awareness on the disease and modes of transmission and weak epidemiological surveillance\[[@B7],[@B8]\]; (2) Barriers in providing access to diagnostics and surveillance systems\[[@B7],[@B9]\]; (3) Lack of adequate and updated national guidelines/strategies or other regulatory directives on the diagnosis and management of viral hepatitis and HCV infection\[[@B6]-[@B10]\]; (4) Fear of treatment side effects\[[@B8]\]; and (5) High treatment cost and lack of reimbursement coverage for treatment\[[@B8],[@B9]\].

This primary aim of this consensus document is to guide physicians on the diagnosis and treatment of chronic HCV infection and to ensure the optimal use of cost-effective regimens in resource-limited settings in Ukraine and CIS countries.

METHODOLOGY OF CONSENSUS DEVELOPMENT
====================================

On 9 April 2018, on the sidelines of the European Association for the Study of the Liver 2018 conference, a panel of experts in the field of hepatology from four countries in the Ukraine/CIS region (Uzbekistan, Ukraine, Belarus, and Kazakhstan) convened at Holiday Inn Paris-St. Germain des Près to review the updated literature on the management of HCV infection and to provide recommendations to optimize the: (1) Diagnosis of HCV infection; (2) Use of cost-effective treatment regimens for the management of HCV infection in resource-limited settings in Ukraine and CIS regions; and (3) Pre-, on-, and posttreatment assessments during HCV management.

The recommendations for the use of optimal treatment regimens in the management of HCV infection in Ukraine and the CIS region were graded by the expert panel as "Preferred," "Alternative," or "Not Recommended" (Table [1](#T1){ref-type="table"}).

###### 

Definitions of the grading of the recommendations

  **Grading**       **Definition**
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preferred         Treatment can be used in most patients and recommendation is based on optimal efficacy, favorable tolerability, toxicity profiles, treatment duration, and pill burden
  Alternative       Treatment can be the one that is effective but with potential disadvantages/limitations in certain patient populations or with less supporting data as compared with the recommended regimens; in certain situations, an alternative regimen may be an optimal regimen for a specific patient population
  Not recommended   Treatment is clearly inferior compared with the recommended or alternative regimens because of factors such as lower efficacy, unfavorable tolerability, toxicity, longer duration, and/or higher pill burden. Unless otherwise indicated, such regimens should not be administered in HCV-infected patients

HCV: Hepatitis C virus.

OPTIMIZING THE DIAGNOSIS OF HCV INFECTION
=========================================

Diagnosis of HCV infection
--------------------------

**Consensus recommendations on the diagnosis of HCV infection:** (1) Anti-HCV testing is recommended for the screening/initial testing of HCV infection. If the result is positive, the current infection should be confirmed with a sensitive HCV ribonucleic acid (RNA)/core antigen test; (2) Qualitative HCV RNA testing is a reasonable, good, and cost-effective method; it can replace quantitative testing in most patients; (3) It is important to consider quantitative viremia in immunocompromised patients; and (4) Genotyping is recommended to guide appropriate selection of the antiviral regimen.

Key international guidelines recommend initial HCV serological testing for the detection of anti-HCV antibodies and the diagnosis of HCV infection\[[@B11]-[@B13]\]. In case of a positive HCV test result, the diagnosis of chronic HCV infection may be established with a nucleic acid test or a sensitive nucleic acid diagnostic assay that detects HCV RNA\[[@B11]-[@B13]\]. In low- and middle-income countries, the use of a qualitative HCV RNA assay has been found to be feasible for providing broader access to HCV diagnosis and care\[[@B12]\]. A less sensitive alternative to the HCV RNA test for the diagnosis of HCV infection is the detection of the HCV core antigen\[[@B12]\]. The results of initial HCV serological testing may be negative in some HCV-infected cases (*e.g*., in case of early acute infection, in immunocompromised patients, or in patients on hemodialysis). In these patients, HCV RNA testing should be a part of the initial assessment\[[@B12]\].

Whenever the staging of hepatitis C is deemed necessary, the degree of liver fibrosis/cirrhosis should be assessed using liver biopsy or other noninvasive tests\[[@B1],[@B13]\]. In resource-limited settings, however, the use of liver biopsy may be limited due to cost, invasiveness, and plausible complications, whereas the use of noninvasive tests, such as transient elastography, may be limited by cost and availability constraints. In these settings, serum noninvasive tests, such as the aminotransferase/platelet ratio index (APRI) or fibrosis-4 score, may be useful\[[@B11],[@B13]\]. The APRI has been found to have sufficient sensitivity and specificity for predicting cirrhosis\[[@B14]\]. Besides the detection of liver fibrosis/cirrhosis, testing and detection of the HCV genotype should also be conducted to guide decisions on the choice of treatment\[[@B1],[@B13]\].

Screening of HCV infection
--------------------------

Owing to the high prevalence of HCV infection in Ukraine and the CIS region, periodic screening programs should be conducted to detect infected individuals and to ensure a timely management of the disease. According to the Centers for Disease Control and Prevention, routine HCV screening is not recommended for the general population, pregnant women, healthcare workers, or nonsexual contacts of HCV-positive individuals\[[@B2]\]. Serological testing for HCV may be offered to adults born between 1945 and 1965, high-risk individuals, and those with a history of HCV risk exposure or behavior\[[@B2],[@B11],[@B13]\]. In individuals with a positive anti-HCV test result, further confirmation of the diagnosis of HCV infection should be made with an HCV RNA or HCV core antigen assay. Rapid diagnostic tests using serum, plasma, fingerstick whole blood, or saliva may be considered as alternatives to standard enzyme immu-noassays\[[@B12]\].

OPTIMIZING THE MANAGEMENT OF HCV INFECTION
==========================================

The treatment of HCV infection should focus on: (1) Achievement of sustained virologic response (SVR); (2) Education in liver-associated adverse effects, such as hepatic cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC); (3) Management of extrahepatic manifestations; and (4) Reduction in mortality rate\[[@B11]\]. SVR is defined as the continued absence of detectable HCV RNA and/or HCV core antigen for at least 12 wk after the completion of therapy\[[@B11]\].

Pretreatment assessments
------------------------

**Consensus recommendations on pre-treatment assessments:** (1) Liver fibrosis assessment: The use of liver biopsy and/or noninvasive markers is recommended for deciding on the regimen and the need for initiating additional measures for the management of cirrhosis (*e.g*., HCC screening); (2) Assessment for potential drug-drug interactions with concomitant medications is recommended; and (3) Recommended laboratory tests: Complete blood count; hepatic function tests \[albumin, total and direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase, and alkaline phosphatase levels\], international normalized ratio, calculated glomerular filtration rate (GFR), creatinine levels, hepatitis B surface antigen (HBsAg) test, tests for hepatitis B surface antibody (anti-HBs) and antibody to hepatitis B core antigen, additional test for PCR hepatitis B virus (HBV) DNA (quantitative, if the qualitative test yields positive results) in patients with HBsAg and/or antibody to hepatitis B core antigen positivity, and alpha-fetoprotein in patients with cirrhosis.

Pretreatment assessments for optimizing the choice of therapy should include the assessment of virologic parameters and the severity of liver disease. Other important parameters that must be assessed to guide treatment selection include alcohol intake, HBV/human immunodeficiency virus (HIV) co-infection, renal impairment, diabetes mellitus, autoimmunity, and cardiac diseases\[[@B12]\]. Alcohol consumption should be assessed, and, if needed, counseling should be provided to correct the same\[[@B12]\].

Treatment of HCV infection with direct-acting antivirals (DAAs) may result in reactivation of HBV infection in patients with HCV-HBV co-infection\[[@B13],[@B15]-[@B18]\]. Patients with HCV-HBV co-infection have been noted to have accelerated progression of liver disease and an increased risk of HCC\[[@B11],[@B13],[@B19],[@B20]\]. However, reactivation of HBV and subsequent hepatitis has been found to be rare in HCV-HBV co-infected patients who are HBsAg-negative or those who have baseline HBV DNA \< 2000 IU/mL prior to DAA therapy\[[@B21]-[@B24]\]. Therefore, the expert panel recommended that all HCV patients with positive HBsAg/anti-HBs should be tested for HBV DNA (quantitative, if the qualitative test yields positive results). Patients who fulfil the standard treatment criteria for HBV should be initiated on HBV antiviral treatment. Other patients should be monitored periodically by the assessment of HBV DNA and ALT during HCV DAA therapy. Antiviral therapy for HBV infection should be initiated if patients develop HBV reactivation (presence of HBsAg and HBV DNA plus elevation in ALT more than the upper limit of normal\[[@B12]\]. A recent systematic review and meta-analysis has suggested that anti-HBV prophylaxis with tenofovir or entecavir may significantly reduce the risk of HBV reactivation in patients receiving DAA-based treatment\[[@B24]\].

Rapid progression of fibrosis has been noted in individuals with HCV-HIV co-infection. Persistent elevation of liver enzymes, especially aspartate aminotransferase, has been found to be a useful marker to predict the progression of fibrosis in these individuals\[[@B25]\]. Therefore, all individuals with HCV infection should be evaluated for HIV infection prior to deciding on the choice of therapy\[[@B11]-[@B13]\]. The plausibility of drug-drug interactions between DAAs and anti-retroviral therapy should be carefully considered in HCV-HIV-co-infected patients, and the choice and dose of DAAs should be optimized accordingly\[[@B11],[@B12]\].

Several extrahepatic manifestations may occur in patients with HCV infection. Hence, these individuals should be assessed for plausible comorbidities, such as renal impairment, diabetes mellitus, autoimmunity, and cardiac diseases\[[@B12]\]. Additionally, assessment of HCV RNA or HCV core antigen and staging of fibrosis/cirrhosis are also important prior to the initiation of treatment for HCV infection. Furthermore, HCV genotype testing may be useful in guiding treatment selection and optimizing treatment outcomes\[[@B11],[@B12]\].

Who should be treated?
----------------------

Treatment should be initiated in all individuals with chronic HCV infection, except in patients with a limited life expectancy that cannot be improved by treatment or transplantation. Patients with decompensated cirrhosis should be managed by an expert with relevant clinical experience\[[@B11]\].

DAAs available in Ukraine and the CIS region
--------------------------------------------

Pegylated interferon (peg-IFN) and ribavirin are still used and listed as first-line medications in Ukraine and some CIS countries. First-generation DAAs, such as boceprevir and telaprevir, that are no longer recommended are also registered in most CIS countries. One or more second-generation DAAs are available in Ukraine and in the majority of CIS regions\[[@B6]\]. A summary of the DAA regimens available in Ukraine and in some CIS regions, as compiled by the expert panel, is presented in Table [2](#T2){ref-type="table"}. The pharmacological features of the DAAs available in this region have been described in Figure [1](#F1){ref-type="fig"}\[[@B26]-[@B29]\].

![Pharmacological features of direct-acting antiviral agents available in Ukraine and some Commonwealth of Independent States regions. DAA: Direct-acting antiviral agents; CIS: Commonwealth of Independent States; HCV: Hepatitis C virus; RNA: Ribonucleic acid; Tmax: Time required to reach the peak plasma concentration of the drug; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir; ESRD: End-stage renal disease; OD: Once-daily; CYP: Cytochrome P; MOA: Mechanism of action.](WJG-25-3897-g001){#F1}

###### 

Direct-acting antivirals available in Ukraine and specific Commonwealth of Independent States countries

  **Country**   **SOF**   **LDV/SOF**   **DCV**
  ------------- --------- ------------- ---------
  Uzbekistan    **√**     **√**         **√**
  Ukraine       **√**     **√**         
  Belarus       **√**     **√**         **√**
  Kazakhstan    **√**     **√**         **√**

SOF: Sofosbuvir; DCV: Daclatasvir; LDV: Ledipasvir.

Treatment of patients with HCV GT1 infection
--------------------------------------------

The regimens proposed for the treatment of patients with chronic HCV GT1 infection are listed in Table [3](#T3){ref-type="table"}.

###### 

Recommended treatment regimens for hepatitis C virus GT1 infection

  **Recommendation category**                                                                                                                                                                    **Treatment option/s**                                                                                                  **Treatment regimens**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Preferred                                                                                                                                                                                      LDV + SOF ± RBV                                                                                                         **LDV + SOF for 12 wk**
  In treatment-naïve patients having HCV RNA \< 6 million IU/mL in whom cirrhosis has been conclusively ruled out by transient elastography (FibroScan) or biopsy: LDV + SOF for 8 wk                                                                                                                                    
  In treatment-experienced cirrhotic patients/patients with decompensated liver disease/postliver transplant patients: LDV + SOF + RBV for 12 wk (or) LDV + SOF for 24 wk if RBV is ineligible                                                                                                                           
  Alternative                                                                                                                                                                                    SOF + DCV ± RBV                                                                                                         SOF + DCV for 12 wk (addition of RBV may be considered if cirrhosis has not been conclusively ruled out)
  In patients with compensated cirrhosis: SOF + DCV ± weight-based RBV for 24 wk                                                                                                                                                                                                                                         
  In patients with decompensated cirrhosis: SOF + DCV + RBV for 12 wk (or) SOF + DCV for 24 wk if RBV is ineligible                                                                                                                                                                                                      
  Not recommended                                                                                                                                                                                Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.   

SOF: Sofosbuvir; LDV: Ledipasvir; DAAs: Direct-acting antivirals; DCV: Daclatasvir; RBV: Ribavirin; RNA: Ribonucleic acid.

**Sofosbuvir + ledipasvir ± ribavirin:** Sofosbuvir in combination with ledipasvir, with or without ribavirin, has been evaluated for the treatment of HCV GT1 infection in several clinical studies worldwide. The phase III ION-1 trial studied the efficacy of this regimen taken for 12 wk or 24 wk in previously untreated, chronic HCV GT1-infected patients (*n* = 865). About 67% of the patients had GT1a infection, and 16% had cirrhosis. Eligible patients were randomized in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir fixed-dose combination once daily for 12 wk or 24 wk, or ledipasvir-sofosbuvir + ribavirin for 12 wk or 24 wk. The primary endpoint of SVR at 12 wk after the end of treatment was 99%, 98%, 97%, and 99%, respectively, in the four treatment groups. In patients with cirrhosis, the rates of SVR ranged from 94% to 100% in the four treatment groups\[[@B30]\]. Several other clinical and real-world studies and meta-analyses have also reported the efficacy of this regimen in treating HCV GT1-infected patients, including: (1) Both treatment naïve and treatment-experienced patients\[[@B31]-[@B49]\]; (2) Patients with compensated cirrhosis or advanced liver disease\[[@B31],[@B36],[@B38],[@B40],[@B44]-[@B46],[@B48],[@B50]-[@B52]\]; and (3) Liver transplantation cases (the transplantation cases studied included treatment-naïve as well as treatment-experienced and those with cirrhosis and HCC prior to transplantation)\[[@B50],[@B53]-[@B59]\]. The presence of fibrosis, cirrhosis, or HCC has been found to lower the SVR rates with sofosbuvir and ledipasvir combination in HCV GT1-infected patients in a few studies\[[@B56],[@B58]-[@B62]\].

The phase III, open-label, randomized, ION-3 trial demonstrated that sofosbuvir in combination with ledipasvir given for a shorter duration of 8 wk to treatment- naïve HCV GT1-infected patients without cirrhosis achieved a 94% SVR rate, comparable to the same regimen given for 12 wk, or given in combination with ribavirin for 8 wk\[[@B63]\]. The effectiveness of the 8-wk regimen in the specified population has also been proven in other clinical and real-world studies\[[@B31],[@B64]-[@B68]\].

The ION-4 trial was a multicenter, single-group, open-label study conducted to assess the effectiveness of sofosbuvir and ledipasvir fixed-dose combination in patients co-infected with HIV-1 and HCV GT1 or GT4 infection (*n* = 335; 55% were previously treated for HCV infection, and 20% had cirrhosis). The study demonstrated a 96% SVR rate at 12 wk after the treatment in patients with HCV GT1a and a 96% SVR rate in patients with HCV GT1b infection. The SVR rates were not affected by previous treatment or cirrhosis status\[[@B69]\]. High SVR rates have also been reported with this regimen in several other clinical and real-world studies in HCV GT1 individuals co-infected with HIV, including: (1) Both treatment-naïve and treatment-experienced patients\[[@B42],[@B70]-[@B72]\] and (2) Those with cirrhosis\[[@B73],[@B74]\].

The use of a ribavirin-free sofosbuvir and ledipasvir combination regimen has been found to be associated with a significant improvement in the quality of life in HCV GT1-infected patients, regardless of the treatment history or the presence of cirrhosis or HIV co-infection\[[@B75]-[@B78]\]. An increase in toxicity has been noted with the inclusion of ribavirin in the treatment regimen\[[@B75],[@B79]\].

The efficacy and safety of sofosbuvir and ledipasvir combination has also been tested in HCV GT1-infected patients with severe renal insufficiency, including those undergoing dialysis and kidney transplantation with favorable tolerability and SVR rates\[[@B56],[@B80]-[@B85]\]. Of note, the safety and SVR rates with this regimen have been noted to be better among noncirrhotic *versus* cirrhotic HCV GT1-infected patients with renal conditions, in a few studies\[[@B56],[@B84]\].

**Sofosbuvir + daclatasvir ± ribavirin:** Sofosbuvir + daclatasvir with or without ribavirin has been evaluated in several clinical studies in varied HCV GT1-infected patient populations. This regimen, provided for 12 wk or 24 wk to treatment-naïve (*n* = 126) and for 24 wk to treatment-experienced (*n* = 41) HCV GT1-infected patients, has been found to result in high SVR rates (98%) in the open-label AI444040 trial\[[@B86]\]. Another open-label, phase III trial, viz. ALLY-1, included 76% HCV GT1-infected patients with: (1) Cirrhosis (compensated/decompensated) or (2) Postliver transplantation recurrence. The study evaluated the sofosbuvir, daclatasvir, and ribavirin combination regimen for 12 wk. In patients with cirrhosis interrupted by liver transplantation, treatment was extended for an additional period of 12 wk after transplantation. The SVR rates were 82% and 95% in patients with cirrhosis and liver transplant recipients, respectively. The regimen was well-tolerated, with no treatment-related serious adverse events\[[@B87]\]. In real-world settings and large-scale, multicentric studies, an optimal duration of 12 wk and 24 wk has been suggested with this regimen in noncirrhotic and cirrhotic HCV GT1-infected patients, respectively, for achieving favorable SVR rates\[[@B47],[@B88]\]. The efficacy and safety of this regimen have also been proven in other clinical and real-world studies and meta-analyses that enrolled HCV GT1-infected patients, including treatment-experienced patients, patients with cirrhosis or advanced liver disease, and liver transplant recipients\[[@B46],[@B49],[@B57],[@B89]-[@B95]\]. The SVR rates in a few studies were found to be lower in cirrhotic *versus* noncirrhotic HCV GT1-infected patients treated with this regimen\[[@B46],[@B96]\].

The daclatasvir + sofosbuvir regimen has also been found to be effective, with high SVR rates in HCV GT1 patients co-infected with HIV, including treatment-experienced patients, patients with advanced liver disease, and patients undergoing liver transplantation\[[@B74],[@B97]-[@B103]\].

Several studies have evaluated the use of this regimen in HCV GT1-infected patients with renal conditions. The combination of sofosbuvir and daclatasvir has been found to be well-tolerated and effective for the treatment of HCV GT1-infected patients with severe renal insufficiency, including those on dialysis or undergoing renal transplantation\[[@B80],[@B85],[@B104]-[@B107]\]. Furthermore, a pangenotypic regimen of daclatasvir and half-daily dose of sofosbuvir has been found to be effective for the treatment of HCV GT1-infected patients with an estimated GFR (eGFR) \< 30 mL/min with favorable SVR rates (SVR12: 90%-100%)\[[@B105],[@B108]\]. In pharmacokinetic studies, it has been noted that an impaired eGFR (30-60 mL/min) may not lead to the dose accumulation of sofosbuvir in HCV-positive kidney transplant recipients or hemodialysis patients\[[@B109],[@B110]\]. Studies may be needed in future to understand further the kinetic profile of sofosbuvir-based treatment in HCV-positive end-stage kidney disease patients or renal transplant recipients.

Treatment of patients with HCV GT2 infection
--------------------------------------------

The preferred regimens recommended by the expert panel for the treatment of patients with chronic HCV GT2 infection are given in Table [4](#T4){ref-type="table"}.

###### 

Recommended preferred treatment regimens for hepatitis C virus GT2 infection

  **Recommendation category**                                                                                                        **Treatment option(s)**                                                                                                 **Treatment regimen**
  ---------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------
  Preferred                                                                                                                          SOF + DCV ± RBV                                                                                                         SOF + DCV for 12 wk in noncirrhotics
  In decompensated cirrhosis and previous failures:                                                                                                                                                                                                          
  SOF + DCV + RBV for 12 wk                                                                                                                                                                                                                                  
  SOF + RBV                                                                                                                          SOF + RBV for 12 wk in noncirrhotics                                                                                    
  To be extended to 24 wk in cirrhotics and treatment failures (Data are not available for patients with decompensated cirrhosis.)                                                                                                                           
  Should be considered as an alternative regimen when DCV is not available                                                                                                                                                                                   
  Not recommended                                                                                                                    Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.   

DAAs: Direct-acting antivirals; DCV: Daclatasvir; RBV: Ribavirin; SOF: Sofosbuvir.

**Sofosbuvir + daclatasvir ± ribavirin:** The AI444040 trial (cited earlier) also included 26 treatment-naïve HCV GT2-infected patients who were treated with the sofosbuvir + daclatasvir regimen with or without ribavirin for 24 wk. SVR was attained in about 92% of these patients\[[@B86]\]. In the ALLY-1 trial, the SVR rate in HCV GT2-infected patients with cirrhosis treated with the sofosbuvir, daclatasvir, and ribavirin combination for 12 wk was 80%\[[@B87]\]. One hundred percent SVR rate was noted in another retrospective study conducted in HCV GT2-infected patients treated with the sofosbuvir and daclatasvir regimen (*n* = 13), regardless of the degree of baseline fibrosis. The treatment was also found to induce improvement in fibrosis in these patients\[[@B111]\]. The effectiveness of this regimen in treating HCV GT2-infected patients has been proven in routine clinical settings, with an SVR of 88.1%-100% and 94.5%-100% with daclatasvir and sofosbuvir combination with and without ribavirin, respectively\[[@B112],[@B113]\]. Studies have also evaluated the efficacy and safety of this regimen in patients with recurrent HCV GT2 infection post liver transplantation and have reported favorable SVR rates, but the number of patients tested is very low to draw any clinically relevant conclusions in this setting\[[@B103]\].

In HCV GT2-infected patients who cannot tolerate ribavirin, the use of sofosbuvir and daclatasvir for 12 wk in noncirrhotic patients, and for 24 wk in cirrhotic patients, including those with decompensated disease, has been found to achieve high SVR rates 12 wk after the treatment\[[@B114]\].The efficacy of the 12 wk sofosbuvir + daclatasvir regimen has also been proven in patients with HCV GT2 infection, co-infected with HIV-1\[[@B97],[@B98]\].

One hundred percent SVR rate was achieved and no deterioration of renal function was noted in HCV GT2-infected patients with chronic kidney disease treated with sofosbuvir + daclatasvir ± ribavirin regimen\[[@B113]\], and 100% SVR rate was noted in HCV GT2-infected patients with end-stage renal disease (eGFR \< 30 mL/min) with daclatasvir full dose plus low-dose sofosbuvir regimen\[[@B105]\]. However, the number of patients evaluated in these studies is too small, and the results need to be substantiated with larger, well-designed studies in future.

**Sofosbuvir + ribavirin:** The VALENCE trial enrolled HCV GT2- or GT3-infected patients (*n* = 419; 58% were previously treated with an IFN-based regimen and 21% had cirrhosis). Of the 419 patients, about 91 HCV GT2-infected patients were randomized in a 4:1 ratio to receive sofosbuvir + ribavirin or placebo for 12 wk. The primary endpoint was SVR at 12 wk after the therapy. The study findings revealed that the SVR rate was 93% in HCV GT2-infected patients treated with the sofosbuvir + ribavirin regimen\[[@B115]\]. Several other randomized and real-world studies have also reported high SVR rates with the sofosbuvir and ribavirin regimen (12 wk or 16 wk duration) in HCV GT2-infected patients, regardless of the treatment history or the presence of cirrhosis\[[@B96],[@B116]-[@B120]\]. However, the presence of cirrhosis or a history of HCC was found to influence negatively the SVR rates in some real-world studies\[[@B121]-[@B124]\].

The efficacy of 48 wk of sofosbuvir and ribavirin combination regimen, given prior to liver transplantation (due to HCC), on the prevention of HCV recurrence post transplantation was assessed in an open-label study in 61 HCV-infected patients (GT2; *n* = 8). A total of 46 liver transplantations were done, of which 43 had HCV RNA level \< 25 IU/mL at the time of transplantation (GT2; *n* = 6). The primary endpoint of HCV RNA level \< 25 IU/mL at 12 wk after transplantation was achieved by all GT2-infected patients, with no evidence of HCV recurrence\[[@B125]\]. In a separate case study, a patient with liver transplant graft re-infected with HCV GT2 infection was safely and successfully treated with sofosbuvir and ribavirin combination regimen\[[@B126]\].

In randomized phase III studies, a treatment extension of about 24 wk with sofosbuvir and ribavirin regimen has been found to result in 100% SVR rates in treatment-experienced, cirrhotic HCV GT2-infected patients\[[@B118]\]. An extended-duration regimen has also been tested in real-world settings; treatment of treatment-naïve or treatment-experienced HCV GT2-infected patients with cirrhosis for up to 20 wk with this regimen resulted in 94.9% SVR rates\[[@B127]\].

The use of this regimen for the treatment of previously untreated and treatment-experienced HCV GT2-infected patients co-infected with HIV-1 for 12 wk and 12 wk or 24 wk, respectively, has been found to yield high SVR rates\[[@B128],[@B129]\].

A recent study evaluated the efficacy and safety of sofosbuvir and ribavirin regimen in 231 HCV GT2-infected patients with renal dysfunction (82.8% and 17.2% with chronic kidney disease stage G1/2, and G3, respectively). While the overall SVR rate was 97%, the SVR rate in chronic kidney disease stages G1, G2, G3a, and G3b were 98.1%, 98.6%, 87.9%, and 100%, respectively. Multivariate analysis revealed that baseline renal dysfunction significantly and negatively influenced the SVR rates, thus suggesting the need for monitoring of baseline renal function in HCV GT2-infected patients treated with this regimen\[[@B130]\].

Treatment of patients with HCV GT3 infection
--------------------------------------------

The preferred and alternative regimens for the treatment of HCV GT3 infection are listed in Table [5](#T5){ref-type="table"}.

###### 

Recommended treatment regimens for hepatitis C virus GT3 infection

  **Recommendation category**                                                                                                  **Treatment option(s)**                                                                                                 **Treatment regimen**
  ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Preferred                                                                                                                    SOF + DCV ± RBV                                                                                                         SOF + DCV for 12 wk (addition of RBV may be considered if cirrhosis has not been conclusively ruled out)
  In patients with compensated cirrhosis                                                                                                                                                                                                               
  Treatment-naïve patients: SOF + DCV + RBV for 24 wk if patients can tolerate ribavirin well, if not SOF+DCV for 24 wk                                                                                                                                
  Treatment-experienced patients: SOF + DCV + RBV for 24 wk if patients tolerated ribavirin well, if not SOF + DCV for 24 wk                                                                                                                           
  In patients with decompensated cirrhosis:                                                                                                                                                                                                            
  SOF + DCV + RBV for 12 wk                                                                                                                                                                                                                            
  If RBV is ineligible: SOF + DCV for 24 wk                                                                                                                                                                                                            
  Alternative                                                                                                                  SOF + RBV                                                                                                               SOF + RBV for 24 wk (should be considered only when preferred regimens are not available)
  LDV + SOF + RBV                                                                                                              LDV + SOF + RBV for 12 wk (should be considered only when preferred regimens are not available)                         
  Not recommended                                                                                                              Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.   

DAAs: Direct-acting antivirals; DCV: Daclatasvir; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir.

**Sofosbuvir + daclatasvir ± ribavirin:** While the AI444040 trial reported an 89% SVR rate in 18 treatment-naïve HCV GT3-infected patients treated with this regimen for 24 wk, the ALLY-1 trial that enrolled both treatment-naïve and treatment-experienced patients reported an 83% SVR rate in HCV GT3-infected patients with cirrhosis (*n* = 6) and a 91% SVR rate in liver transplant recipients with posttransplant recurrence of HCV GT3 infection (*n* = 11)\[[@B86],[@B87]\]. The phase III ALLY-3 trial evaluated the once-daily, 12 wk sofosbuvir + daclatasvir regimen in HCV GT3-infected patients \[previously untreated (*n* = 101) and treatment-experienced (*n* = 51)\]. The SVR rates were 90% and 86% in treatment-naïve and treatment-experienced patients, respectively. About 19% of patients in the treatment-naïve and 25% of patients in the treatment-experienced groups had cirrhosis in this study. The SVR rates were 96% and 63% in patients without and with cirrhosis, respectively\[[@B131]\]. The ALLY-3+ trial was a randomized, phase III trial that included both treatment-naïve and treatment-experienced GT3-infected patients with advanced fibrosis or compensated cirrhosis. The efficacy and safety of daclatasvir + sofosbuvir with ribavirin given for either 12 wk or 16 wk were assessed in this trial. The SVR rates were 88% and 92% in the groups treated with the 12-wk regimen and the 16-wk regimen, respectively. In patients with cirrhosis, the corresponding SVR rates were 83% and 89%, respectively. Previous treatment had no influence on the SVR rates\[[@B132]\]. The ALLY-3C trial was a single-arm, phase III study that evaluated the efficacy and safety of sofosbuvir + daclatasvir + ribavirin regimen given for 24 wk in HCV GT3-infected patients with compensated cirrhosis. While the SVR12 rate was 87% in the primary analysis, the rates in treatment-naïve and treatment-experienced patients were 93% and 79%, receptively. The regimen was well-tolerated\[[@B133]\]. In real-world settings, treatment of HCV GT3-infected patients, including cirrhotic and treatment-experienced patients, and liver transplant recipients (with a history of HCC prior to transplantation) with recurrent cirrhosis, with this regimen has been found to result in high SVR rates\[[@B46],[@B56],[@B57],[@B91],[@B112],[@B134]-[@B144]\].

The efficacy and safety of the daclatasvir + sofosbuvir regimen have also been proven in treatment-naïve and treatment-experienced HCV GT3-infected patients co-infected with HIV-1, including those with advanced liver disease and recurrent HCV after liver transplantation\[[@B73],[@B97]-[@B99],[@B101],[@B103],[@B140]\].

High SVR rates have been reported with the use of this regimen in HCV GT3-infected patients with advanced chronic kidney disease with an eGFR \< 30 mL/min or those on dialysis\[[@B80]-[@B82],[@B104]\]. Further, a regimen comprising low-dose sofosbuvir and full dose daclatasvir has been found to be safe and effective in achieving high SVR rates in HCV GT3-infected patients with eGFR \< 30 mL/min or those on maintenance hemodialysis\[[@B105],[@B108],[@B145]\]. Full or half-dose sofosbuvir + daclatasvir regimen has also been evaluated in HCV GT3-infected renal transplant recipients with 100% SVR rates\[[@B85]\]. However, the number of patients included in all these studies are small, and large-scale studies may be needed to corroborate the significance of these findings.

**Sofosbuvir + ribavirin:** The VALENCE trial enrolled HCV GT2 (*n* = 91) or GT3 (*n* = 328)-infected patients and randomized them in a 4:1 ratio to receive sofosbuvir-ribavirin or placebo. The duration of treatment for GT3-infected patients was 24 wk. The study findings revealed high SVR rates (85%) in HCV GT3-infected patients\[[@B115]\]. The response rates were 91% and 68% in GT3-infected patients without and with cirrhosis, respectively\[[@B115]\]. Another prospective study reported an overall SVR rate of 99.2% in GT3-infected HCV patients who received sofosbuvir and ribavirin for 24 wk\[[@B146]\]. In a Russian phase IIIb study, treatment of HCV GT3-infected patients with sofosbuvir + ribavirin for 16 wk or 24 wk was found to be safe and associated with 87% and 90% SVR12 rates, respectively\[[@B147]\]. In a recent real-world study, treatment of HCV GT3-infected patients (*n* = 110) (51 with compensated and 59 with decompensated cirrhosis) with sofosbuvir + ribavirin for 24 wk resulted in achievement of SVR in 83.3% and 71.4% of treatment-naïve and treatment-experienced patients with compensated cirrhosis, respectively; and 77.8% and 75% of treatment-naïve and treatment-experienced patients with decompensated cirrhosis, respectively. The combination was well-tolerated; however, the outcomes in decompensated and treatment-experienced patients were noted to be suboptimal\[[@B148]\]. This combination regimen given for 24 wk was safe and effective in achieving 95% SVR12 and 94% SVR24 in HCV GT3-infected liver transplant recipients with recurrent HCV infection\[[@B149]\]. Administration of this regimen 48 wk before liver transplantation resulted in 80% of HCV GT3-infected patients achieving HCV RNA \< 25 IU/mL 12 wk post transplantation\[[@B125]\].

In HCV GT3-infected patients co-infected with HIV, sofosbuvir and ribavirin regimen has been reported to be associated with significantly lower SVR12 when compared to daclatasvir and sofosbuvir regimen\[[@B150]\]. Literature is sparse on the safety and efficacy of this combination in HCV GT3-infected patients with renal conditions.

**Sofosbuvir + ledipasvir + ribavirin:** In an open-label trial, 12 wk of the sofosbuvir, ledipasvir, and ribavirin regimen administered to treatment-naïve (*n* = 26) and treatment-experienced (*n* = 50) HCV GT3-infected patients resulted in 100% and 82% SVR rates, respectively\[[@B151]\]. In another open-label trial, treatment-naïve HCV patients with and without compensated cirrhosis were treated with sofosbuvir, ledipasvir, and weight-based ribavirin for 12 wk. About 95% of the patients had GT3a infection. The overall SVR rate was 89%, with 79% and 94% SVR rates in patients with and without cirrhosis, respectively\[[@B152]\]. Real-world studies have reported ≥ 90% SVR12 rate with this regimen in HCV GT3-infected patients, including those with cirrhosis and advanced or compensated liver disease\[[@B46],[@B134],[@B140]-[@B142],[@B153]\].

Evidence on the efficacy and safety of this regimen in HCV GT3-infected patients co-infected with HIV is limited to a few real-world studies\[[@B73],[@B140],[@B153]\], in which the SVR rates have been reported to be 100%, \> 90%, and 80% in patients without and with compensated or decompensated cirrhosis, respectively\[[@B73]\].

Studies on the efficacy and safety of this regimen in HCV GT3-infected liver transplant recipients or patients with renal conditions are limited.

Treatment of patients with HCV GT4 infection
--------------------------------------------

The treatment options for HCV GT4-infected patients listed in Table [6](#T6){ref-type="table"} have been recommended by the expert panel.

###### 

Recommended treatment regimens for hepatitis C virus GT4 infection

  **Recommendation category**                                            **Treatment option(s)**                                                                                                 **Treatment regimen**
  ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preferred                                                              LDV + SOF ± RBV                                                                                                         LDV + SOF for 12 wk \[Addition of RBV may be considered based on the physician's discretion in treating difficult-to-treat patients (treatment-experienced patients, patients with cirrhosis)\].
  In case of previous SOF treatment failure: LDV + SOF + RBV for 12 wk                                                                                                                           
  Alternative                                                            SOF + DCV ± RBV                                                                                                         SOF + DCV for 12 wk (Addition of RBV may be considered if cirrhosis has not been conclusively ruled out.)
  Cirrhosis of any class: SOF + DCV + RBV for 12 wk                                                                                                                                              
  If RBV is ineligible, SOF + DCV for 24 wk                                                                                                                                                      
  Not recommended                                                        Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.   

DAAs: Direct-acting antivirals; DCV: Daclatasvir; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir.

**Sofosbuvir + ledipasvir + ribavirin:** Several phase II studies have established the efficacy of the 12-wk sofosbuvir and ledipasvir regimen in the treatment of HCV GT4-infected patients, regardless of the treatment history or the presence of cirrhosis\[[@B154],[@B155]\]. Administering the combination of this regimen with ribavirin for 12 wk or 24 wk also resulted in high SVR rates in phase II studies on HCV GT4-infected patients with advanced liver diseases\[[@B77]\]. Similarly, high SVR rates have been noted in a phase III study that used a 12-wk sofosbuvir and ledipasvir regimen with or without ribavirin for the treatment of HCV GT4-infected and cirrhotic patients (including both treatment-naïve and treatment-experienced patients)\[[@B156]\]. In another cohort study, the sofosbuvir and ledipasvir combination administered for 12 wk was associated with a 99% SVR rate in HCV GT4-infected patients\[[@B157]\]. In real-world studies and meta-analyses, favorable SVR rates have been noted with the sofosbuvir and ledipasvir regimen with or without ribavirin given for 12 wk or 24 wk in HCV GT4-infected patients, including treatment-naïve and treatment-experienced patients\[[@B49],[@B158],[@B159]\] and patients with advanced liver fibrosis and compensated and decompensated cirrhosis\[[@B158],[@B159]\]. The addition of ribavirin has not been found to improve the efficacy of the combination regimen\[[@B158],[@B159]\]. In a recent real-world study, an 8-wk regimen of ledipasvir + sofosbuvir was found to be well-tolerated and effective in treatment-naïve and noncirrhotic HCV GT4-infected patients (*n* = 45) (SVR12: 97.8%)\[[@B160]\]. Studies evaluating the efficacy of sofosbuvir + ledipasvir + ribavirin regimen in HCV GT4-infected liver transplant recipients are limited.

The ION-4 trial was a large phase III trial that enrolled HCV GT1- or GT4-infected patients co-infected with HIV-1 who were treated with the sofosbuvir and ledipasvir regimen for 12 wk. About 55% of the patients were treatment-experienced, and 20% had cirrhosis. The SVR rate was noted to be 100% in the GT4-infected patients\[[@B69]\]. In real-world studies, treatment of HCV GT4-infected patients co-infected with HIV with ledipasvir and sofosbuvir regimen was associated with 96%, 94%, and 80% SVR rate in patients without cirrhosis and with compensated and decompensated cirrhosis, respectively\[[@B73]\].

Very few studies have evaluated the efficacy of sofosbuvir + ledipasvir ± ribavirin in HCV GT4-infected renal transplant recipients. One hundred percent SVR12 rates have been noted in these studies with good safety profile of the regimen\[[@B83],[@B85]\]. However, the number of patients evaluated in these studies is too small, and results from studies in larger patient populations may be needed to translate these findings to clinical practice.

**Sofosbuvir + daclatasvir ± ribavirin:** In the ALLY-1 trial, the combination of sofosbuvir + daclatasvir with ribavirin for 12 wk or 24 wk was associated with a 100% SVR rate in GT4-infected patients with cirrhosis\[[@B87]\]. In another cohort study, the sofosbuvir and daclatasvir combination for 12 wk was associated with a 96% SVR in HCV GT4-infected patients\[[@B161]\]. A separate prospective study categorized HCV GT4-infected patients into two groups: Group 1 included treatment-naïve patients treated with sofosbuvir + daclatasvir for 12 wk; and group 2 included treatment-experienced patients treated with sofosbuvir + daclatasvir + ribavirin for 12 wk (sofosbuvir-experienced patients were treated for 24 wk). The SVR12 rate was 93.3% and 87.5% in groups 1 and 2, respectively. A significant improvement in liver fibrosis was also noted with the treatment in this study\[[@B162]\]. Real-world studies have also supported the efficacy of this combination regimen (with or without ribavirin) with high SVR rates in HCV GT4-infected patients\[[@B103],[@B163],[@B164]\], including those with decompensated cirrhosis and HCV recurrence after liver transplantation\[[@B103],[@B163]\].

Daclatasvir + sofosbuvir has also been found to result in favorable SVR rates in HCV GT4-infected patients co-infected with HIV-1, including those with cirrhosis and advanced liver disease\[[@B73],[@B97]-[@B101]\].

Studies evaluating the efficacy and safety of this regimen in HCV GT4-infected patients with renal conditions are limited.

Treatment of patients with HCV GT5 or GT6 infections
----------------------------------------------------

The preferred and alternative regimens for the treatment of HCV GT5 or GT6 infections are listed in Table [7](#T7){ref-type="table"}.

###### 

Recommended treatment regimens for hepatitis C virus GT5 or GT6 infections

  **Recommendation category**                                            **Treatment option(s)**                                                                                                 **Treatment regimen**
  ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preferred                                                              LDV + SOF ± RBV                                                                                                         LDV + SOF for 12 wk \[Addition of RBV may be considered based on the physician's discretion in treating difficult-to-treat patients (treatment-experienced patients, patients with cirrhosis)\].
  In case of previous SOF treatment failure: LDV + SOF + RBV for 12 wk                                                                                                                           
  Alternative                                                            SOF + DCV ± RBV                                                                                                         SOF + DCV for 12 wk (Addition of RBV may be considered if cirrhosis has not been conclusively ruled out.)
  Cirrhosis of any class: SOF + DCV + RBV for 12 wk                                                                                                                                              
  If RBV is ineligible, SOF + DCV for 24 wk                                                                                                                                                      
  Not recommended                                                        Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.   

DAAs: Direct-acting antivirals; DCV: Daclatasvir; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir.

**Sofosbuvir + ledipasvir ± ribavirin:** The regimen of sofosbuvir and ledipasvir without ribavirin was evaluated in a single-arm, open-label, phase II trial, in GT5-infected treatment-naïve and treatment-experienced patients, including those with cirrhosis (*n* = 41). The treatment was provided for 12 wk. While the overall SVR rate with the combination was found to be 95%, the SVR rates in patients with and without cirrhosis were 89% and 97%, respectively\[[@B165]\]. Another prospective, open-label, multicentric study evaluated the efficacy and safety of ledipasvir and sofosbuvir combination given for 8 wk or 12 wk in 60 HCV GT6-infected patients. There were two patients with decompensation, three with liver cancer, and 14 with prior treatment exposure in the 12-wk group. The SVR12 rate was 95% in both the 8- wk and 12-wk treatment groups, and the regimen was found to be safe\[[@B166]\]. In another study conducted by Gane et al\[[@B151]\], the combination was evaluated with or without ribavirin for 12 wk in 126 treatment-naïve or treatment-experienced patients with HCV GT3 or GT6 infection (*n* = 25 for GT6). The SVR rate in patients with HCV GT6 infection was 96%. Recent real-world studies, systematic reviews, and meta-analyses have also reported high SVR rates (up to 100%) in HCV GT6-infected patients treated with this combination\[[@B47],[@B49],[@B167]\].

There is limited evidence on the efficacy and safety of this combination in HCV GT6-infected patients undergoing liver transplantation or with concomitant renal conditions.

**Sofosbuvir + daclatasvir ± ribavirin:** Data on the use of this regimen in the treatment of HCV GT5- or GT6-infected patients are limited. In the open-label ALLY-1 study, SVR was achieved in a single GT6-infected liver transplant recipient treated with the combination\[[@B87]\]. Real-world studies and systematic reviews have reported 94%-100% SVR rate with daclatasvir and sofosbuvir combination in HCV GT6-infected patients\[[@B47],[@B167],[@B168]\]. Data on the efficacy of this combination in HCV GT6-infected kidney transplant recipients are limited to studies with very limited patient population\[[@B169]\].

On- and posttreatment assessments
---------------------------------

The expert panel recommended several on- and posttreatment assessments that should be conducted during the management of HCV infection (Table [8](#T8){ref-type="table"}).

###### 

On- and posttreatment assessments during the management of hepatitis C virus infection

  **Assessments**                                                                                                                                                                     **Expert recommendations**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  On-treatment                                                                                                                                                                        In patients with cirrhosis, CBC, creatinine level, estimated GFR, and hepatic function panel may be repeated after 4 wks
  All patients on RBV should have CBC done at four and 8 wk to monitor for hemolysis                                                                                                  
  HCV RNA testing (qualitative/quantitative) may not be required, as there are no current recommendations for response-guided therapy. Testing at the end of treatment is mandatory   
  Assessment of potential drug-drug interactions with concomitant medications is recommended                                                                                          
  A periodic review of therapy compliance and the general condition of the patient is recommended                                                                                     
  Posttreatment                                                                                                                                                                       SVR should be assessed at 12 wk or 24 wk after the end of treatment
  In patients who have failed therapy:                                                                                                                                                
  Disease progression (hepatic function panel, CBC, and INR) should be assessed once in 6-12 mo                                                                                       
  In patients with advanced fibrosis (Metavir stages F3 or F4), screening for hepatocellular carcinoma with ultrasound is recommended every 6 mo                                      
  Endoscopic screening for esophageal varices is recommended in cirrhotic patients                                                                                                    
  In patients who achieve SVR:                                                                                                                                                        
  In patients with advanced fibrosis (Metavir stage F3 or F4), screening for hepatocellular carcinoma with ultrasound is recommended in every 6 mo                                    
  Endoscopic screening for esophageal varices is recommended in cirrhotic patients with pretreatment varices or portal hypertensive gastropathy                                       
  AFP as a screening test for HCC is recommended in cirrhotic patients                                                                                                                

CBC: Complete blood count; GFR: Glomerular filtration rate; RBV: Ribavirin; RNA: Ribonucleic acid; SVR: Sustained virologic response; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

On-treatment assessments help monitor treatment efficacy and safety, evaluate drug-drug interactions, and ensure medication adherence. In all HCV-infected patients receiving DAA-containing regimens (with or without ribavirin or peg-IFN), complete blood count, renal function tests, and hepatic function panel test should be conducted 4 wk after therapy initiation. Assessment for any side effects or drug-drug interactions, and treatment adherence, is also recommended in the fourth week of treatment\[[@B13]\]. In patients treated with ribavirin-containing regimens, complete blood count should be conducted at 4 wk and 8 wk of therapy to assess for any significant drop in hemoglobin levels\[[@B12],[@B13]\]. Considering the resource-limited settings in the CIS and Ukraine regions, and the lack of any standard recommendations, the expert panel did not recommend HCV RNA testing during treatment\[[@B12],[@B13]\]. However, the panel recommended HCV RNA testing at the end of therapy\[[@B11]\].

Posttreatment follow-up and assessment help confirm the elimination of the virus and prevent relapses. The expert panel recommended the assessment of HCV RNA at 12 wk or 24 wk after completion of therapy, for evaluation of SVR12 or SVR24, in line with the other international recommendations\[[@B11]-[@B13]\]. Furthermore, the panel provided posttreatment assessment recommendations for two categories of patients: (1) Those who have failed the therapy and (2) Those who achieved SVR.

Patients who fail the therapy not only remain carriers of the virus but also experience continued liver injury and fibrosis progression\[[@B170]\]. The incidence of death or liver transplantation can be as high as 12.2% in patients with advanced fibrosis and 31.5% among patients with cirrhosis\[[@B170]\]. Therefore, it is important to systematically assess reasons for failure of therapy in these patients. Such patients should also be followed up regularly to assess disease progression. Furthermore, patients with advanced fibrosis (Metavir stage F3 or F4) should be evaluated for HCC every 6 mo using ultrasound surveillance\[[@B12]\].

Among patients who have achieved SVR, those with advanced fibrosis (Metavir stage F3 or F4) should be evaluated for HCC every 6 mo using ultrasound surveillance. Furthermore, patients with cirrhosis should be screened endoscopically for esophageal varices and evaluated with alpha-fetoprotein test to screen for HCC\[[@B12],[@B13]\].

A SHORT NOTE ON HCV DRUG RESISTANCE
===================================

The emergence of HCV variants with substitutions associated with resistance to DAAs is critical and is particularly noted with NS5A inhibitor-containing regimens. These substitutions are termed resistance-associated substitutions (RAS). Resistant HCV viruses that are enriched in patients with DAA therapy failure contain substitutions termed treatment-emergent RAS. Both baseline and treatment-selected RAS may negatively impact the response rate and treatment outcomes\[[@B11],[@B13]\]. The RAS in the NS5A position for HCV genotypes 1a and 3 are currently considered clinically significant. Methods to detect RAS include population (Sanger) sequencing and deep sequencing \[next generation sequencing\], with 15% prevalence of RAS as the recommended cutoff\[[@B11]\].

Access to reliable HCV resistance testing techniques is limited in the resource constraint settings of Ukraine and CIS regions. Hence, no consensus could be formed on the methods of HCV resistance testing and reporting, and no recommendations could be made on the systematic testing for HCV resistance prior to DAA treatment or monitoring for HCV drug resistance during or after therapy. However, the following approaches were proposed to help overcome resistance: (1) Optimal risk stratification of patients, based on prior treatment, or degree of cirrhosis; (2) Determination of HCV genotype and subtype so as to help optimize the treatment approach; (3) Optimization of treatment duration and careful selection of patients for short-duration therapy; (4) Addition of ribavirin in selected populations, such as those with prior DAA failure or at risk of treatment failure, and those with baseline NS5A RAS; and (5) Optimal selection of DAA therapy combinations\[[@B11],[@B13]\].

CONCLUSION
==========

In Ukraine and the CIS regions, several challenges hinder the optimal management of HCV infection, including the lack of sufficient epidemiological data, the disparity in genotype distribution, barriers in access to diagnostics, lack of updated national guidelines, and financial constraints. The use of peg-IFN, ribavirin, and first-generation DAAs is still prevalent in these regions, with very few second-generation DAAs being available in most of the regions. There is a clear unmet need for the development of a guidance document for the optimal screening, diagnosis, monitoring, and management of HCV infection with the use of cost-effective, available DAA regimens. The current consensus document compiles the evidence-based recommendations on the diagnosis and management of HCV infection provided by key opinion leaders (from Ukraine and the CIS regions) in the field of hepatology. This document will help guide clinical decision-making on the diagnosis, treatment, and pre-, on-, and posttreatment assessments of HCV infection, further optimizing the treatment outcomes in these regions.
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